Valeant finds second maker for Methoxsalen; Teva consolidating plants;

> Valeant Pharmaceuticals ($VRX) says the FDA has approved a second manufacturer for methoxsalen USP, used in the treatment of psoriasis, that previously had been in short supply. Release

> In its earnings call, Teva ($TEVA) said it was going through a "rationalization plan" worldwide and will close a number of its 120 plants over the next two to three years. It reported that at 32% decline in generic revenues in the U.S. came in part from quality and supply issues from plants in Irvine and Jerusalem. Release | Earnings transcript

> Sanofi's ($SNY) Genzyme unit has recalled one batch of the leukemia drug Fludara made at the closed Ben Venue Laboratories plant in Bedford, OH, due to concerns about its sterility--the latest in a series of supply and quality issues at the plant. Story

> Johnson & Johnson ($JNJ) continued to market an artificial hip in Europe and elsewhere overseas after the FDA rejected it in the U.S. based on a review of company safety studies. News

> Asymchem Laboratories has opened a $20M manufacturing facility called Jilin Asymchem Laboratories, in Dunhua, PR China. Story

> Lonza says a deal for a partnership with South Africa to build an API plant is still being negotiated. Item

> Hospitals are torn over federal rules for discarding expired but scarce drugs. Report

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.